Get the Stockscreener App
7.16
4.28%
-0.32
After Hours:
7.17
0.010
+0.14%
Acurx Pharmaceuticals Inc stock is traded at $7.16, with a volume of 246.68K.
It is down -4.28% in the last 24 hours and up +66.13% over the past month.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
See More
Previous Close:
$7.48
Open:
$7.23
24h Volume:
246.68K
Relative Volume:
0.53
Market Cap:
$11.35M
Revenue:
-
Net Income/Loss:
$-14.58M
P/E Ratio:
-6.2261
EPS:
-1.15
Net Cash Flow:
$-9.80M
1W Performance:
+67.29%
1M Performance:
+66.13%
6M Performance:
+1.04%
1Y Performance:
-82.71%
1-Day Range:
$6.80
$7.98
1-Week Range:
$4.10
$8.34
52-Week Range:
$3.80
$42.80
Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile
Name
Acurx Pharmaceuticals Inc
Sector
Industry
Phone
917-533-1469
Address
259 LIBERTY AVENUE, STATEN ISLAND
Compare ACXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACXP
Acurx Pharmaceuticals Inc
|
7.16 | 11.85M | 0 | -14.58M | -9.80M | -1.15 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Acurx Pharmaceuticals Inc Stock (ACXP) Latest News
Multi factor analysis applied to Acurx Pharmaceuticals Inc.2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com
Can Acurx Pharmaceuticals Inc. (3ZO) stock test all time highsMarket Activity Recap & Technical Analysis for Trade Confirmation - newser.com
Will Acurx Pharmaceuticals Inc. stock split attract more investors2025 Price Targets & Weekly High Momentum Picks - newser.com
What Fibonacci levels say about Acurx Pharmaceuticals Inc. reboundGlobal Markets & Smart Swing Trading Alerts - newser.com
Quantitative breakdown of Acurx Pharmaceuticals Inc. recent moveTrade Exit Summary & Entry Point Confirmation Alerts - newser.com
Acurx Pharmaceuticals Inc.’s volatility index tracking explainedMarket Volume Summary & Weekly Momentum Stock Picks - newser.com
New to The Street Broadcasts Tonight on Bloomberg Featuring Roadzen, Metaterra, NRx Pharma, Blackbarn NYC, and Humanitarian Travel Group - Kansas City Star
Acurx Pharmaceuticals (NASDAQ:ACXP) Raised to Hold at Wall Street Zen - Defense World
How Acurx Pharmaceuticals Inc. (3ZO) stock reacts to fiscal policiesWeekly Profit Summary & Weekly High Conviction Trade Ideas - newser.com
Acurx Pharmaceuticals granted Australian patent for antibiotics - Investing.com Australia
Acurx Pharmaceuticals granted Australian patent for antibiotics By Investing.com - Investing.com Nigeria
Australian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors - Stock Titan
Measuring Acurx Pharmaceuticals Inc.’s beta against major indicesJuly 2025 Levels & Verified Swing Trading Watchlist - newser.com
What drives Acurx Pharmaceuticals Inc stock pricePrice-to-Earnings Ratio Insights & High Return Market Tips - earlytimes.in
Pharma Boom: Acurx on the Rise - StocksToTrade
ACXP’s Steady Climb: New Developments? - timothysykes.com
90% Plunge to 1000% Upside? Acurx Pharmaceuticals (ACXP) Stock Sees EMA Boost & Bold Analyst Predictions - ts2.tech
Why Confluent Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Resigns with New to The Street for Long-Form Interviews, National TV Commercials, Earned Media, and Accredited Investor Events - Corpus Christi Caller-Times
Will breakout in Acurx Pharmaceuticals Inc. lead to full recoveryPortfolio Update Summary & Daily Technical Stock Forecast Reports - newser.com
Acurx Pharmaceuticals Inc Stock Analysis and ForecastInterest Rate Changes & Build Capital Safely - earlytimes.in
How supply shortages influence Acurx Pharmaceuticals Inc. (3ZO) stockInsider Buying & Weekly Stock Performance Updates - newser.com
Acurx Pharmaceuticals Inc. stock trendline breakdownChart Signals & Long-Term Investment Growth Plans - newser.com
Why retail investors favor Acurx Pharmaceuticals Inc. stockPortfolio Gains Report & Reliable Breakout Stock Forecasts - newser.com
Will Acurx Pharmaceuticals Inc. stock outperform Nasdaq indexJuly 2025 Spike Watch & Daily Chart Pattern Signal Reports - newser.com
New to The Street to Broadcast Nationwide on Bloomberg Tonight at 6:30 PM EST - Sacramento Bee
Acurx Pharmaceuticals (NASDAQ:ACXP) Lowered to Sell Rating by Wall Street Zen - Defense World
Will Acurx Pharmaceuticals Inc. (3ZO) stock return to pre crash levels2025 Price Action Summary & Comprehensive Market Scan Insights - newser.com
Chart overlay techniques for tracking Acurx Pharmaceuticals Inc.2025 Support & Resistance & Consistent Profit Alerts - newser.com
Acurx Pharmaceuticals stock maintains Buy rating at H.C. Wainwright By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals stock maintains Buy rating at H.C. Wainwright - Investing.com
EMA approves Acurx’s pediatric plan for C. difficile drug ibezapolstat By Investing.com - Investing.com Nigeria
Acurx Pharmaceuticals (NASDAQ:ACXP) Given “Buy” Rating at HC Wainwright - Defense World
H.C. Wainwright Maintains Acurx Pharmaceuticals(ACXP.US) With Buy Rating, Maintains Target Price $31 - 富途牛牛
Promising Outlook for Acurx Pharmaceuticals: Buy Rating Driven by Regulatory Milestones and Clinical Success of Ibezapolstat - TipRanks
EMA approves Acurx’s pediatric plan for C. difficile drug ibezapolstat - Investing.com
Acurx Pharmaceuticals, Inc. Announces Positive Opinion from EMA on Pediatric Investigation Plan for Ibezapolstat Use in Children with C. Difficile Infection - MarketScreener
DYAI Stock Analysis and ForecastVolume Profile Analysis & Start Investing With Free Smart Watchlists - earlytimes.in
20,000 Children Affected Annually: Acurx's New Antibiotic Gets Key EMA Support for C. difficile Treatment - Stock Titan
Acurx Pharmaceuticals Inc Stock (ACXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acurx Pharmaceuticals Inc Stock (ACXP) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Sailer Carl | Director |
Jan 06 '25 |
Buy |
1.01 |
24,631 |
25,000 |
137,183 |
| LUCI DAVID P | President and CEO |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,097,458 |
| Donohue James J. | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
22,352 |
| DELUCCIA ROBERT J | Director |
Jan 06 '25 |
Buy |
1.01 |
49,261 |
50,000 |
1,010,196 |
| DEAN JACK H | Director |
Jan 06 '25 |
Buy |
1.01 |
9,852 |
10,000 |
21,776 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):